4M Therapeutics
4M Therapeutics is a biotechnology company specializing in the discovery and development of targeted therapies for neuropsychiatric and neurodegenerative diseases such as bipolar disorder and Alzheimer's disease. Leveraging a human brain cell platform derived from induced pluripotent stem cells, the company advances small molecule and peptide drug candidates that modulate pathways involved in neuronal health. 4M Therapeutics integrates biomarker-driven drug development and strong academic collaborations to enable predictive and safe preclinical drug discovery, aiming to advance targeted CNS therapies with improved safety and efficacy profiles.
Industries
N/A
Products
Oral small molecule inhibitor of GSK3β with enhanced potency and selectivity, developed for mood disorders and neurodegenerative indications, and derived from a de-risked metabolite of ruboxistaurin.
Series of small molecule inhibitors with potent and specific activity against GSK3β, with application to agitation in Alzheimer's disease and other neurodegenerative conditions.
Peptide-based inhibitors of the CDK5/p25 complex, shown to be active in preclinical models of tau pathology, with potential relevance for neurodegenerative disease therapy.
Oral small molecule inhibitor of GSK3β with enhanced potency and selectivity, developed for mood disorders and neurodegenerative indications, and derived from a de-risked metabolite of ruboxistaurin.
Series of small molecule inhibitors with potent and specific activity against GSK3β, with application to agitation in Alzheimer's disease and other neurodegenerative conditions.
Peptide-based inhibitors of the CDK5/p25 complex, shown to be active in preclinical models of tau pathology, with potential relevance for neurodegenerative disease therapy.
Expertise Areas
- Neuropsychiatric drug discovery
- Neurodegenerative disease therapeutics
- CNS biomarker development
- Induced pluripotent stem cell modeling
Key Technologies
- Human iPSC-derived neural cell models
- High-content phenotypic screening
- GSK3β small molecule inhibitors
- CDK5/p25 peptide inhibitors
Key People
Scientific Founder
Scientific Founder
Scientific Founder; Chair of Scientific Advisory Board
Chief Executive Officer, Founder & Director
Chief Business Officer
Chief Financial Officer
Scientific Founder
Scientific Founder
Scientific Founder; Chair of Scientific Advisory Board
Chief Executive Officer, Founder & Director
Chief Business Officer
Chief Financial Officer
Investors
SYNGAP RESEARCH FUND
$120,000 funded.
Announced on 2024-11-12.
SYNGAP RESEARCH FUND
$120,000 funded.
Announced on 2024-11-12.
News & Updates
Recognized as a finalist in the regional Startup World Cup competition.
Named Startup of the Year by the Princeton, NJ chapter of Startup Grind.
Listed among the top promising life sciences companies at the Texas Life Science Forum.
Raised $2.575 million, surpassing initial target to advance preclinical and clinical programs.
Article on therapeutic targets and mechanisms related to bipolar disorder drug development.
Publication on translational hIPSC models for bipolar disorder research.
Recognized as a finalist in the regional Startup World Cup competition.
Named Startup of the Year by the Princeton, NJ chapter of Startup Grind.
Listed among the top promising life sciences companies at the Texas Life Science Forum.
Raised $2.575 million, surpassing initial target to advance preclinical and clinical programs.
Article on therapeutic targets and mechanisms related to bipolar disorder drug development.
Publication on translational hIPSC models for bipolar disorder research.